Search alternatives:
reduction decrease » reduction decreased (Expand Search), reduction reuse (Expand Search), production increases (Expand Search)
significant use » significant cause (Expand Search), significant i.e (Expand Search), significantly used (Expand Search)
use increased » cases increased (Expand Search), also increased (Expand Search), rate increased (Expand Search)
Showing 1 - 20 results of 122,822 for search '(( significant reduction decrease ) OR ( significant use increased ))', query time: 1.47s Refine Results
  1. 1
    M<sup>pro</sup> confers a significant reduction in growth in yeast caused by decreases in a variety of cellular proteins.

    M<sup>pro</sup> confers a significant reduction in growth in yeast caused by decreases in a variety of cellular proteins. by Jin Ou (16914305)

    Published 2023
    Save to List
    Saved in:
  2. 2
    Aripiprazole significantly decreases phosphorylated Src (Y416) levels in dHL-60 cells.

    Aripiprazole significantly decreases phosphorylated Src (Y416) levels in dHL-60 cells. by Courtney A. Swain (15170264)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 3
    T lymphocyte populations significantly increased in APRIL<sup>-/-</sup>/BLyS<sup>-/-</sup> group.

    T lymphocyte populations significantly increased in APRIL<sup>-/-</sup>/BLyS<sup>-/-</sup> group. by Natalie M. Bath (6316517)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  4. 4
    Early-stage and mature B lymphocytes significantly decreased but long-lived B lymphocytes increased in APRIL<sup>-/-</sup>/BLyS<sup>-/-</sup> group.

    Early-stage and mature B lymphocytes significantly decreased but long-lived B lymphocytes increased in APRIL<sup>-/-</sup>/BLyS<sup>-/-</sup> group. by Natalie M. Bath (6316517)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  5. 5
    Comparison of brain volume reduction assessed using head computed tomography between admission and follow-up.

    Comparison of brain volume reduction assessed using head computed tomography between admission and follow-up. by Toru Hosokawa (364158)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  6. 6
    A: Additional statistical information for significant comparisons for positive affect increase in moderate trait anxiety participants.

    A: Additional statistical information for significant comparisons for positive affect increase in moderate trait anxiety participants. by Adiel Mallik (12219281)

    Published 2022
    Save to List
    Saved in:
  7. 7
    Trends in the days of third-generation cephalosporin therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of third-generation cephalosporin therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  8. 8
    Trends in the incidence of extended-spectrum β-lactamase (ESBL)- producing Enterobacteriaceae per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the incidence of extended-spectrum β-lactamase (ESBL)- producing Enterobacteriaceae per 1000 patients, by month, during the pre-intervention period (Phase 1) and interven... by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  9. 9
    Trends in the incidence of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the incidence of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional pe... by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  10. 10
    Trends in the days of sulfamethoxazole-trimethoprim therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of sulfamethoxazole-trimethoprim therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  11. 11
    Trends in the incidence of penicillin-resistant <i>Streptococcus pneumoniae</i> (PRSP) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the incidence of penicillin-resistant <i>Streptococcus pneumoniae</i> (PRSP) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional... by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  12. 12
    Average purchase costs of 3GCs and all oral antimicrobials per 100 patient-days from Phases 1–4.

    Average purchase costs of 3GCs and all oral antimicrobials per 100 patient-days from Phases 1–4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  13. 13
    Trends in the incidence of resistant <i>Haemophilus influenzae</i> per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the incidence of resistant <i>Haemophilus influenzae</i> per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).... by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  14. 14
    S1 Dataset -

    S1 Dataset - by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  15. 15
    Trends in the incidence of <i>Clostridioides difficile</i> infection (CDI) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the incidence of <i>Clostridioides difficile</i> infection (CDI) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phas... by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  16. 16
    Trends in in-hospital mortality by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in in-hospital mortality by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  17. 17
    Pop-up for oral 3GC prescription.

    Pop-up for oral 3GC prescription. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  18. 18
    Trends in the days of cefalexin therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of cefalexin therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  19. 19
    Trends in the days of quinolone therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of quinolone therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  20. 20
    Trends in the length of hospital stay by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the length of hospital stay by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:

Search Tools: